ADC Therapeutics Plummets Over 50% on Phase 3 Trial Data
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: seekingalpha
- Trial Results Impact: ADC Therapeutics' Phase 3 LOTIS-5 trial showed a median progression-free survival of 6.1 months for Zynlonta combined with rituximab, significantly higher than the control group's 4.7 months; however, the overall survival did not demonstrate superiority, leading to a drastic market reaction with shares plummeting over 50% in premarket trading.
- Safety Concerns: While the rate of treatment-emergent adverse events was similar between the groups (98.5% vs. 97.5%), the experimental arm had a significantly higher rate of serious adverse events at 49.0%, which may affect physician acceptance of the therapy and negatively impact future sales.
- Regulatory Path Dependency: The continued availability of Zynlonta in the U.S. hinges on positive results from confirmatory trials, and ADC Therapeutics plans to submit a supplemental Biologics License Application based on trial data; failure to secure FDA approval could severely impact the company's revenue.
- Cost Control Measures: The company indicated it will continue its cost reduction initiatives and other value-enhancing measures to navigate current market challenges, emphasizing the need to maintain operational sustainability despite significant stock price declines.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADCT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADCT
Wall Street analysts forecast ADCT stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.170
Low
5.00
Averages
7.33
High
10.00
Current: 3.170
Low
5.00
Averages
7.33
High
10.00
About ADCT
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. It employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The Company has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. It serves customers in the United States, Switzerland, and the United Kingdom.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADC Therapeutics Plummets Over 50% on Phase 3 Trial Data
- Trial Results Impact: ADC Therapeutics' Phase 3 LOTIS-5 trial showed a median progression-free survival of 6.1 months for Zynlonta combined with rituximab, significantly higher than the control group's 4.7 months; however, the overall survival did not demonstrate superiority, leading to a drastic market reaction with shares plummeting over 50% in premarket trading.
- Safety Concerns: While the rate of treatment-emergent adverse events was similar between the groups (98.5% vs. 97.5%), the experimental arm had a significantly higher rate of serious adverse events at 49.0%, which may affect physician acceptance of the therapy and negatively impact future sales.
- Regulatory Path Dependency: The continued availability of Zynlonta in the U.S. hinges on positive results from confirmatory trials, and ADC Therapeutics plans to submit a supplemental Biologics License Application based on trial data; failure to secure FDA approval could severely impact the company's revenue.
- Cost Control Measures: The company indicated it will continue its cost reduction initiatives and other value-enhancing measures to navigate current market challenges, emphasizing the need to maintain operational sustainability despite significant stock price declines.
See More
ADC Therapeutics Reports LOTIS-5 Trial Results for ZYNLONTA
- Clinical Trial Success: ADC Therapeutics' LOTIS-5 trial demonstrated that the combination of ZYNLONTA and rituximab achieved statistical significance in progression-free survival (PFS) with a median PFS of 6.1 months compared to 4.7 months in the control group, indicating a significant therapeutic effect.
- Efficacy Metrics Improvement: The combination therapy showed a complete response (CR) rate of 39.5% versus 26.7% in the control group, highlighting its potential to provide a new treatment option for patients by significantly enhancing response rates.
- Safety Analysis: While the treatment-emergent adverse event (TEAE) rates were similar between the ZYNLONTA plus rituximab group (98.5%) and the control group (97.5%), the higher rate of serious adverse events (SAEs) in patients aged 75 and older in the ZYNLONTA group indicates a need for careful risk assessment in elderly patients.
- FDA Application Plans: Following the positive results from LOTIS-5, ADC Therapeutics plans to submit a supplemental Biologics License Application (sBLA) in Q4 2026 and will hold a pre-sBLA meeting with the FDA in August to discuss the benefit-risk profile of this combination.
See More
ADC Therapeutics Q1 2026 Earnings Call Insights
- Revenue Growth: In Q1 2026, ADC Therapeutics reported net product revenues of $20 million, up from $17.4 million in the same quarter last year, primarily driven by normal fluctuations in customer orders, indicating stable market demand and the company's ability to maintain strong sales momentum in a competitive environment.
- Cost Management: The cost of product sales rose to $3.6 million in the first quarter, an increase of $1.6 million from the previous quarter, reflecting a shift in personnel cost allocation from research and development to commercial manufacturing, while the company actively optimizes its cost structure to maintain financial health.
- Cash Flow Status: As of the end of Q1 2026, ADC Therapeutics had cash and cash equivalents of $231 million, down from $261.3 million at the end of 2025, yet still maintaining a healthy cash flow that supports future R&D and market expansion initiatives.
- Future Outlook: Management expects to share top-line data for LOTIS-5 by the end of June, and if results are positive, plans to submit a supplemental biologics license application to the FDA by year-end, demonstrating the company's confidence in new product launches and its strategic grasp of market opportunities.
See More
ADC Therapeutics Q1 Financial Results Analysis
- Revenue Performance: ADC Therapeutics reported a Q1 non-GAAP EPS of -$0.13 with revenues of $20.85 million, reflecting a 9.5% year-over-year decline but exceeding expectations by $0.86 million, demonstrating resilience amid market fluctuations.
- Product Revenue Growth: The net product revenue for Q1 reached $20 million, up from $17.4 million in Q1 2025, primarily driven by normal variability in customer ordering patterns and price increases, indicating stability in product demand.
- Decline in License Revenue: License revenues and royalties fell to $0.8 million from $5.6 million in Q1 2025, primarily due to a milestone payment received in the prior year, highlighting the volatility in revenue sources.
- Cash Flow Status: As of March 31, 2026, cash and cash equivalents stood at $231 million, with an expected cash runway extending at least into 2028, ensuring operational stability for the company in the coming years.
See More
ADC Therapeutics Reports Q1 2026 Financial Results and Upcoming Milestones
- Revenue Growth: In Q1 2026, net product revenue reached $20 million, a 15% increase from $17.4 million in Q1 2025, indicating strong sales momentum that could enhance market share in the future amidst normal customer ordering variability.
- Cash Position: As of March 31, 2026, cash and cash equivalents stood at $231 million, down from $261.3 million at the end of 2025, yet the company expects its cash runway to extend into 2028, ensuring sufficient funding for R&D and market expansion.
- R&D Expense Adjustment: Q1 2026 R&D expenses were $19.9 million, a 31% decrease from $28.9 million in Q1 2025, primarily due to reduced external costs and a shift in personnel costs, reflecting strategic resource reallocation within the company.
- Clinical Trial Progress: Topline results from LOTIS-5 are anticipated in Q2 2026, and if positive, the company plans to submit a supplemental Biologics License Application to the FDA by year-end, further advancing ZYNLONTA's application in B-cell malignancies.
See More
ADC Therapeutics Reports Q1 2026 Financial Results and Upcoming Milestones
- Revenue Growth: Net product revenue for Q1 2026 reached $20.0 million, a 15% increase from $17.4 million in Q1 2025, indicating sustained market demand for the ZYNLONTA program, which is expected to drive future revenue growth.
- Cash Position: As of March 31, 2026, the company reported cash and cash equivalents of $231.0 million, with an anticipated cash runway extending at least into 2028, ensuring funding for operational and R&D activities in the coming years.
- Clinical Trial Progress: Topline results from the LOTIS-5 Phase 3 trial are expected in Q2 2026, and if positive, the company plans to submit a supplemental Biologics License Application to the FDA by year-end, further advancing ZYNLONTA's application in diffuse large B-cell lymphoma.
- R&D Expense Adjustment: R&D expenses for Q1 2026 were $19.9 million, down 31% from $28.9 million in Q1 2025, primarily due to reduced external costs and the reallocation of personnel costs, reflecting effective cost control strategies by the company.
See More
ADC Therapeutics Plummets Over 50% on Phase 3 Trial Data
- Trial Results Impact: ADC Therapeutics' Phase 3 LOTIS-5 trial showed a median progression-free survival of 6.1 months for Zynlonta combined with rituximab, significantly higher than the control group's 4.7 months; however, the overall survival did not demonstrate superiority, leading to a drastic market reaction with shares plummeting over 50% in premarket trading.
- Safety Concerns: While the rate of treatment-emergent adverse events was similar between the groups (98.5% vs. 97.5%), the experimental arm had a significantly higher rate of serious adverse events at 49.0%, which may affect physician acceptance of the therapy and negatively impact future sales.
- Regulatory Path Dependency: The continued availability of Zynlonta in the U.S. hinges on positive results from confirmatory trials, and ADC Therapeutics plans to submit a supplemental Biologics License Application based on trial data; failure to secure FDA approval could severely impact the company's revenue.
- Cost Control Measures: The company indicated it will continue its cost reduction initiatives and other value-enhancing measures to navigate current market challenges, emphasizing the need to maintain operational sustainability despite significant stock price declines.
See More
ADC Therapeutics Reports LOTIS-5 Trial Results for ZYNLONTA
- Clinical Trial Success: ADC Therapeutics' LOTIS-5 trial demonstrated that the combination of ZYNLONTA and rituximab achieved statistical significance in progression-free survival (PFS) with a median PFS of 6.1 months compared to 4.7 months in the control group, indicating a significant therapeutic effect.
- Efficacy Metrics Improvement: The combination therapy showed a complete response (CR) rate of 39.5% versus 26.7% in the control group, highlighting its potential to provide a new treatment option for patients by significantly enhancing response rates.
- Safety Analysis: While the treatment-emergent adverse event (TEAE) rates were similar between the ZYNLONTA plus rituximab group (98.5%) and the control group (97.5%), the higher rate of serious adverse events (SAEs) in patients aged 75 and older in the ZYNLONTA group indicates a need for careful risk assessment in elderly patients.
- FDA Application Plans: Following the positive results from LOTIS-5, ADC Therapeutics plans to submit a supplemental Biologics License Application (sBLA) in Q4 2026 and will hold a pre-sBLA meeting with the FDA in August to discuss the benefit-risk profile of this combination.
See More
ADC Therapeutics Q1 2026 Earnings Call Insights
- Revenue Growth: In Q1 2026, ADC Therapeutics reported net product revenues of $20 million, up from $17.4 million in the same quarter last year, primarily driven by normal fluctuations in customer orders, indicating stable market demand and the company's ability to maintain strong sales momentum in a competitive environment.
- Cost Management: The cost of product sales rose to $3.6 million in the first quarter, an increase of $1.6 million from the previous quarter, reflecting a shift in personnel cost allocation from research and development to commercial manufacturing, while the company actively optimizes its cost structure to maintain financial health.
- Cash Flow Status: As of the end of Q1 2026, ADC Therapeutics had cash and cash equivalents of $231 million, down from $261.3 million at the end of 2025, yet still maintaining a healthy cash flow that supports future R&D and market expansion initiatives.
- Future Outlook: Management expects to share top-line data for LOTIS-5 by the end of June, and if results are positive, plans to submit a supplemental biologics license application to the FDA by year-end, demonstrating the company's confidence in new product launches and its strategic grasp of market opportunities.
See More
ADC Therapeutics Q1 Financial Results Analysis
- Revenue Performance: ADC Therapeutics reported a Q1 non-GAAP EPS of -$0.13 with revenues of $20.85 million, reflecting a 9.5% year-over-year decline but exceeding expectations by $0.86 million, demonstrating resilience amid market fluctuations.
- Product Revenue Growth: The net product revenue for Q1 reached $20 million, up from $17.4 million in Q1 2025, primarily driven by normal variability in customer ordering patterns and price increases, indicating stability in product demand.
- Decline in License Revenue: License revenues and royalties fell to $0.8 million from $5.6 million in Q1 2025, primarily due to a milestone payment received in the prior year, highlighting the volatility in revenue sources.
- Cash Flow Status: As of March 31, 2026, cash and cash equivalents stood at $231 million, with an expected cash runway extending at least into 2028, ensuring operational stability for the company in the coming years.
See More
ADC Therapeutics Reports Q1 2026 Financial Results and Upcoming Milestones
- Revenue Growth: In Q1 2026, net product revenue reached $20 million, a 15% increase from $17.4 million in Q1 2025, indicating strong sales momentum that could enhance market share in the future amidst normal customer ordering variability.
- Cash Position: As of March 31, 2026, cash and cash equivalents stood at $231 million, down from $261.3 million at the end of 2025, yet the company expects its cash runway to extend into 2028, ensuring sufficient funding for R&D and market expansion.
- R&D Expense Adjustment: Q1 2026 R&D expenses were $19.9 million, a 31% decrease from $28.9 million in Q1 2025, primarily due to reduced external costs and a shift in personnel costs, reflecting strategic resource reallocation within the company.
- Clinical Trial Progress: Topline results from LOTIS-5 are anticipated in Q2 2026, and if positive, the company plans to submit a supplemental Biologics License Application to the FDA by year-end, further advancing ZYNLONTA's application in B-cell malignancies.
See More
ADC Therapeutics Reports Q1 2026 Financial Results and Upcoming Milestones
- Revenue Growth: Net product revenue for Q1 2026 reached $20.0 million, a 15% increase from $17.4 million in Q1 2025, indicating sustained market demand for the ZYNLONTA program, which is expected to drive future revenue growth.
- Cash Position: As of March 31, 2026, the company reported cash and cash equivalents of $231.0 million, with an anticipated cash runway extending at least into 2028, ensuring funding for operational and R&D activities in the coming years.
- Clinical Trial Progress: Topline results from the LOTIS-5 Phase 3 trial are expected in Q2 2026, and if positive, the company plans to submit a supplemental Biologics License Application to the FDA by year-end, further advancing ZYNLONTA's application in diffuse large B-cell lymphoma.
- R&D Expense Adjustment: R&D expenses for Q1 2026 were $19.9 million, down 31% from $28.9 million in Q1 2025, primarily due to reduced external costs and the reallocation of personnel costs, reflecting effective cost control strategies by the company.
See More
